Treatment of Advanced Melanoma in 2020 and Beyond

Author:

Jenkins Russell W.ORCID,Fisher David E.ORCID

Funder

National Cancer Institute

Melanoma Research Alliance

Cancer Research Foundation

V Foundation

NIH

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference95 articles.

1. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma;Andtbacka;J Clin Oncol,2015

2. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma;Andtbacka;J Immunother Cancer,2019

3. Combination treatment with cobimetnib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (PTS) with BRAFV600 wild type (WT) advanced melanoma: primary analysis from the phase 3 IMSPIRE170 trial;Arance;Ann Oncol,2019

4. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma;Ascierto;Nat Med,2019

5. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999

Cited by 193 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3